Catch up with the Ab Initio Pharma team at DDL 2025

December 10th-13th 2025, Edinburgh International Conference Centre

We are looking forward to connecting with colleagues and partners at this year’s Drug Delivery to the Lung Conference. Ab Initio Pharma will be sharing updates on our expanding end to end capabilities covering inhalation, nasal and advanced lung delivery programs from preclinical development through to GMP manufacture and clinical trial supply.

Our integrated model brings formulation development, device testing, analytical characterisation, stability, pilot to GMP scale up and late phase manufacture together in one workflow. This includes non sterile production, orally and nasally inhaled product development, and full clinical trial services for both Australia and international sites.

If you are exploring new respiratory or nasal programs and want a partner who can take a product from concept to clinic, we would love to meet. Contact Paul Young (CEO) or YY (Hui Xin Ong, COO) to arrange a discussion during DDL through the conference app.